LKKTETQ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Essay about the effect and demonstrations by Jearl Walker (PDF) Site with high-speed video, pictures and explanation of film-boiling by Heiner Linke at the University of Oregon, USA "Scientists make water run uphill" by BBC News about using the Leidenfrost effect for cooling of computer chips. "Uphill Water" – ABC Catalyst story "Leidenfrost Maze" – University of Bath undergraduate students Carmen Cheng and Matthew Guy "When Water Flows Uphill" – Science Friday with Univ. of Bath professor Kei Takashina Jeffrey, Colin (March 10, 2015). "Engine running on frozen carbon dioxide may power mission to Mars". Gizmag. Retrieved 10 March 2015. Carolyn Embach, ResearchGate: English translation of Johan Gottlob Leidenfrost, De aquae communes nonnullis qualitatibus tractatus, Duisburg on Rhine, 1756. (Carolyn S. E. Wares aka Carolyn Embach, translator, 1964)
On June 30, 2009, the song "A Looking in View" was made available for purchase via iTunes and Amazon, and for a limited time it was available as a free download through the official Alice in Chains website in early July. Although it was not the album's first radio single, Rock stations across the U.S. started playing the song. The music video for "A Looking in View" debuted via the band's official website on July 7, 2009. The song was nominated for a Grammy Award for Best Hard Rock Performance. "Check My Brain" was released to radio stations as the first official single from the album on August 14, 2009, and was made available for purchase on August 17, 2009. The music video for "Check My Brain" premiered on September 14, 2009. The song was also nominated for a Grammy Award for Best Hard Rock Performance. To promote the album, the band released an EPK featuring all four of the members being interviewed while the Kiss makeup is being applied on them. An app for iPhone was released on October 27, 2009, featuring songs, music videos, news, photos and networking.
It propped up friendly puppet politicians and supported right-wing militias to maintain power. Workers often organized and went on strike against these conditions, forming local militias against the United Fruit Company. This would usually lead to conflict between the two sides, which culminated in a strike in November 1928 by farmers in Ciénaga for better working conditions. The striking workers called for an end to temporary contracts, the creation of mandatory worker insurance, the creation of compensation for work accidents, the creation of hygienic dormitories, a 6-day work week, the implementation of a minimum wage, the abolishment of wages through company coupons and office stores, and the recognition of farmers and tenants as employees with legal rights. The strike quickly grew, becoming the largest in Colombia's history, with many socialists, anarchists, Marxists, and leftists joining and organizing the strike. The United Fruit Company demanded that the workers and the union disband. Following several weeks of failed negotiations, the Colombian government of Miguel Abadía Méndez sent the Colombian Army to Ciénaga. After a standoff with the strikers, the Army shot into the crowd of strikers, killing between 68 and 2,000 people, in what became known as the Banana Massacre. This led to an outrage in the Colombian public, creating an explosion of leftist and revolutionary organizations. In Bogotá, leftist students protested and organized against the Colombian government, eventually hoping to overthrow it. This opposition exploded in 1948.
Sources: en.wikipedia.org
== Veterinary use == Etorphine is available legally only for veterinary use and is strictly governed by law. It is often used to immobilise elephants and other large mammals. Diprenorphine (Revivon) is an opioid receptor antagonist that can be administered in proportion to the amount of etorphine used (1.3 times) to reverse its effects. Veterinary-strength etorphine is fatal to humans. For this reason the package as supplied to vets always includes the human antidote along with the etorphine. The human antidote is generally naloxone, not diprenorphine, and is always prepared before the preparation of etorphine to be immediately administered following accidental human exposure to etorphine. The LD50 in humans is 3 μg which led to the requirement that the medicine include an equivalent dose of an antidote. One of its main advantages is its speed of operation, and more importantly, the speed that diprenorphine reverses its effects. The high incidence of side effects, including severe cardiopulmonary depression, has caused etorphine to fall into disfavor in general veterinary practice. However, its high potency, combined with the rapid action of both etorphine and its antagonist, diprenorphine, means that it has found a place for use in the capture of large mammals, such as rhinoceroses and elephants, where rapid onset and rapid recovery are both very important. The high potency of etorphine means that sufficient etorphine can be administered to large wild mammals by projectile syringe (dart). Large Animal Immobilon is a combination of etorphine plus acepromazine maleate.
Velmanase alfa, sold under the brand name Lamzede, is a medication used for the treatment of alpha-mannosidosis. Velmanase alfa is a recombinant human lysosomal alpha-mannosidase. The most common adverse reactions include hypersensitivity reactions including anaphylaxis, a severe, potentially life-threatening allergic reaction. Velmanase alfa was approved for medical use in the European Union in March 2018, and in the United States in February 2023. Velmanase alfa is the first enzyme replacement therapy approved in the US for the treatment of the non-central nervous system manifestations of alpha-mannosidosis. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Over the past 20 years, antimicrobial resistance (AMR) has grown, making common infections like respiratory infections, urinary tract infections, STDs, and tuberculosis harder to treat. New antibiotics are not being developed fast enough and may lead to a "post-antibiotic era" where some infections are untreatable. AMR makes infections more difficult and costly to treat. Proper antibiotic use—correct drug, dose, and duration—and strict hospital hygiene are essential. Combating AMR requires cooperation among governments, healthcare workers, researchers, pharmaceutical companies, farmers, and the public through responsible antibiotic use, monitoring resistance, limiting antibiotics in animals, and improving access to medicines, vaccines, and tests. Prevention is the most effective strategy. Along with careful antibiotic use, there is a need for new drugs, alternative treatments, better diagnostics, and vaccines. Without coordinated global action, vital medical procedures like surgery, organ transplants, neonatal care, and cancer treatment could be at risk.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.